Cantor Fitzgerald reiterates Pharvaris stock rating after trial data

Cantor Fitzgerald maintained its Overweight rating on Pharvaris B.V. (NASDAQ:PHVS) and set a $65.00 price target after the company's successful Phase 3 CHAPTER-3 trial. The stock has risen approximately 64% since the beginning of the year, trading at $39.12, approaching its 52-week high of $43.25. Analysts have consistent bullish outlooks, with price targets spanning from $42 to $78.

Cantor Fitzgerald's conference featured Pharvaris management, who addressed safety concerns and shared financial updates. The firm clarified that the single Grade 4 event and serious adverse event in the topline safety data were from the same patient, not a liver-related incident. This patient, with hereditary angioedema, experienced a significant decrease in attacks and returned to work as a pharmacist.

Cantor Fitzgerald highlighted this as a success story for deucrictibant in Type 3 hereditary angioedema. The company's financial position is robust, with more cash than debt, and investors can access 13 exclusive tips, including profitability projections and valuation metrics, through InvestingPro. Pharvaris's Phase 3 trial assessed the once-daily deucrictibant extended-release oral tablet's effectiveness in preventing hereditary angioedema attacks, showing an 83% reduction overall and 87% among patients with Type 1 or Type 2 disease.

Following the positive results, several firms adjusted their price targets, with Guggenheim raising it to $44 (Buy), H.C. Wainwright to $60 (Buy), and Wells Fargo to $65 (Overweight).